Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS To Update Senate Finance Cmte. On Medicare Rx Rules

This article was originally published in The Pink Sheet Daily

Executive Summary

Committee's Sept. 14 hearing also includes testimony from PCMA, AHIP and Business Roundtable. Issues that could be discussed include USP's proposed drug classification system for Medicare and boundaries for health plan coverage.

You may also be interested in...

Medicare Stand-Alone Rx Plans Will Be Available "Everywhere," McClellan Says

CMS will set up a Part D bidding system that will get to the highest level of risk that the market will accept, Administrator McClellan says. "Smaller regions" could encourage drug plan sponsors that are unwilling to take on large capacity, he says.

House Appropriations Subcommittee Plans FDA Hearing July 26

Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.

Second Quarter Earnings Season Heats Up

Amgen, J&J, Sanofi-Aventis, Pfizer, Merck, Roche, Lilly and Schering-Plough are scheduled to report results in upcoming week. Bristol could expand upon plans to sell OTC unit to Novartis the following week.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts